HC Wainwright Has Negative Forecast for uniQure Q1 Earnings

uniQure N.V. (NASDAQ:QURE) – Analysts at HC Wainwright dropped their Q1 2026 EPS estimates for uniQure in a research report issued to clients and investors on Tuesday, March 10th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($0.79) for the quarter, down from their prior estimate of ($0.54). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.43) EPS, FY2027 earnings at ($3.95) EPS, FY2028 earnings at ($3.19) EPS, FY2029 earnings at $0.21 EPS and FY2030 earnings at $4.19 EPS.

Several other equities research analysts also recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $35.00 in a report on Monday. The Goldman Sachs Group cut their price objective on uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Chardan Capital lifted their price target on shares of uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. Finally, Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

uniQure Trading Down 3.8%

NASDAQ:QURE opened at $17.56 on Thursday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -5.09 and a beta of 0.73. The business’s 50-day moving average price is $21.67 and its two-hundred day moving average price is $29.58.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Jefferies Financial Group Inc. bought a new position in shares of uniQure in the second quarter valued at $29,217,000. State Street Corp raised its holdings in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its stake in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $33,062,000. Institutional investors own 78.83% of the company’s stock.

Insiders Place Their Bets

In other news, Director Robert Gut sold 25,613 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 81,399 shares of company stock valued at $1,527,645 in the last quarter. Company insiders own 4.79% of the company’s stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Several analyst upgrades and bullish reports have pushed optimism around the company’s pipeline — Mizuho upgraded QURE to “outperform” with a $35 target (up from $12), and other firms (RBC, Wells Fargo, Chardan) have issued more favorable notes recently, supporting a rebound narrative for the stock. Mizuho Upgrade
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and kept a $70 price target, citing regulatory shifts and AMT‑130 outlook as catalysts that could drive long-term upside. H.C. Wainwright Note
• Neutral Sentiment: Shares previously spiked (~26% reported) on an FDA leadership shakeup that some investors hoped would favor uniQure’s Huntington’s therapy pathway — a short-term momentum event that may have already priced in expectations. MSN Coverage
• Negative Sentiment: Regulatory risk intensified after reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” or “manipulated” data around the failed AMT‑130 program — a serious development that raises oversight, approval, and credibility concerns. FDA Allegation Report
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors for securities‑fraud class actions tied to uniQure’s FDA delays and share decline, creating legal overhang, potential liabilities, and continued headline risk that can pressure the stock. Kessler Topaz Filing
• Negative Sentiment: Short interest jumped significantly in February (over 17% increase), now representing ~21% of float — a condition that can amplify downside on negative news and reflects elevated bearish positioning.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.